Streetbeat News

PIII

P3 Health Partners Inc.

https://p3hp.org

Industry

Medical - Care Facilities

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company is based in Henderson, Nevada.

Open

0.17

Mkt cap

63M

Volume

95K

High

0.18

P/E Ratio

-0.20

52-wk high

1.12

Low

0.17

Div yield

N/A

52-wk low

0.16

P3 Health Partners Inc. (NASDAQ:PIII) has announced a private placement of approximately $42.2 million with institutional investors, including affiliates of Chicago Pacific Founders. The funds will be used for working capital and general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 12:08 pm

P3 Health Partners shares are trading higher following the announcement of a $42.2 million private placement.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 12:07 pm

The article highlights the pre-market movements of various health care stocks on Thursday. Notable gainers include OneMedNet (ONMD), iSpecimen (ISPC), P3 Health Partners (PIII), Bicycle Therapeutics (BCYC), Calliditas Therapeutics (CALT), and AEON Biopharma (AEON). On the losing side, Ensysce Biosciences (ENSC), Cytokinetics (CYTK), DermTech (DMTK), SILO Pharma (SILO), Tango Therapeutics (TNGX), and Vicarious Surgical (RBOT) saw declines.

Portfolio Pulse from Benzinga Insights

May 23, 2024 | 12:06 pm

P3 Health Partners projects its FY24 revenue to be between $1.450 billion and $1.550 billion, compared to the estimated $1.495 billion.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 10:09 pm

P3 Health Partners expects to achieve adjusted EBITDA positivity in 2024 and has reaffirmed its total revenue forecast for the year to be between $1.45 billion and $1.55 billion, aligning with an estimated $1.495 billion.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:51 pm

P3 Health Partners Inc. announced Dr. Aric Coffman as the new CEO effective May 8, 2024, succeeding co-founder Dr. Sherif Abdou. Dr. Abdou will transition to a Strategic Advisor and Board member role. Dr. Coffman, with a strong background in value-based care and leadership roles in healthcare organizations, is expected to continue P3's growth in the Medicare Advantage and ACO market. The leadership transition is part of P3's long-term strategy to enhance its position as a leading value-based care platform.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:12 pm

P3 Health Partners (NASDAQ:PIII) reported Q1 2024 earnings with a GAAP EPS of $(0.16), missing the $(0.11) estimate by 45.45%, but saw a 27.27% improvement from last year's $(0.22) per share. Sales reached $388.488M, exceeding the $352.466M estimate by 10.22% and marking a 28.61% increase from the previous year's $302.077M.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 8:46 pm

In Monday's after-market session, several healthcare stocks showed significant movement. Dynatronics led the gainers with a 70.1% increase, while Poseida Therapeutics experienced the largest drop among the losers, declining by 15.2%. The movements reflect varying market capitalizations and investor reactions to company-specific news or broader market trends.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 8:31 pm

BTIG analyst David Larsen downgraded P3 Health Partners (NASDAQ:PIII) from Buy to Neutral, indicating a shift in the firm's outlook on the company.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 4:12 pm

P3 Health Partners (NASDAQ:PIII) reported Q4 earnings with an EPS of $-0.22, missing estimates by -100.0% against an expected $-0.11. Revenue increased by $88.66 million from the same period last year. Despite missing this quarter's earnings estimate, the company had previously beaten EPS estimates in Q3 2023, which led to a 6.0% share price increase the following day.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.